Diabetes Drugs that Reduce Cardiovascular Disease and Death: Top 10 Medical Innovations 2017
Nearly a decade ago, a wave of new diabetes drugs hit the market with promises of lowering blood sugar. They fell far short of blunting the scariest statistics for type 2 diabetes patients: Half will die from complications from cardiovascular disease. On their 65th birthdays, the odds go up to 70 percent.
In 2016, a couple of new medications began dropping the mortality rates considerably. Empaglifozin proved to modify the progression of heart disease by working with the kidney while liraglutide has a comprehensive effect on many organs.
Given the positive results, experts predict 2017 will mark a complete shift in the lineup of medicines prescribed for diabetes patients, as well as a new wave of research into new avenues to target type 2 diabetes and its comorbidities. With the contribution of these new drugs, more patients will live to see the benefits.